| Therapy | Pre-therapy | 24-week post-therapy | p values (pre- vs. post-) |
---|---|---|---|---|
Adiponectin (μg/mL) | ||||
 | Total SVR patients | 6.53 ± 2.77 | 5.45 ± 2.56 |  < 0.001 |
 | Male SVR patients | 5.85 ± 2.35 | 4.85 ± 2.42 |  < 0.001 |
 | Female SVR patients | 7.15 ± 2.98 | 5.98 ± 2.58 |  < 0.001 |
HOMA-IR | ||||
 | Total SVR patients | 3.25 ± 5.37 | 2.97 ± 3.09 | 0.417 |
 | Male SVR patients | 3.92 ± 7.39 | 3.25 ± 3.70 | 0.491 |
 | Female SVR patients | 2.62 ± 2.03 | 2.71 ± 2.37 | 0.327 |
 | Baseline IR (+ | 1.63 ± 0.51 | 1.99 ± 1.49 | 0.001 |
 | Baseline IR (−) | 5.40 ± 7.69 | 4.29 ± 4.04 | 0.01 |
BMI | ||||
 | Total SVR patients | 24.7 ± 3.9 | 24.9 ± 3.0 | 0.002 |
 | Male SVR patients | 25.2 ± 3.4 | 25.5 ± 3.5 | 0.005 |
 | Female SVR patients | 24.5 ± 4.38 | 24.4 ± 4.51 | 0.155 |
ALT | ||||
 | Total SVR patients | 85.0 ± 94.8 | 23.5 ± 16.0 |  < 0.001 |
 | Male SVR patients | 100.7 ± 121.4 | 24.8 ± 15.0 |  < 0.001 |
 | Female SVR patients | 71.9 ± 60.4 | 21.0 ± 14.6 |  < 0.001 |
eGFR | ||||
 | Total SVR patients | 92.4 ± 38.5 | 87.4 ± 36.4 |  < 0.001 |
 | Male SVR patients | 94.8 ± 38.9 | 88.8 ± 35.8 |  < 0.001 |
 | Female SVR patients | 90.2 ± 38.7 | 85.8 ± 37.6 | 0.045 |